Anti-Pd-1 Antibody Shr-1210 Combined With Apatinib As Adjuvant Treatment In Patients With Hepatocellular Carcinoma At High Risk Of Recurrence After Radical Resection: Preliminary Results From A Multicenter, Randomized, Controlled Phase Ii Trial.

Hong Zhao,Jianjun Zhao,Li Jiang,Xinyu Bi,Honggang Qian,Shunda Du,Jianqiang Cai,Jianguo Zhou,Zhiyu Li,Dongbin Liu,Yubao Zhang,Ping Zhang

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览23

暂无评分

摘要

285Background: There is no globally recognized standard adjuvant therapy for HCC after radical resection. Herein, we explored to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210 comb...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要